|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Last week the FDA advisory committee on Cox-2 drugs ruled that Vioxx should be allowed back on the market, albeit that all drugs in the same class should receive powerful label warnings about potential cardiovascular side-effects.
The Journal says that “[t]his is great news for anyone who might ever have a need for chronic pain management, or indeed an interest in a rational regulatory environment for all future drug development. And it’s a well-deserved rebuke to the nexus of trial lawyers and journalists who whipped up such disproportionate hysteria about the Cox-2s last fall.”
They also praise acting FDA Commissioner Lester Crawford, who allowed 3 days of open hearings on the issue, where everyone, including Cox-2 critics, were given a fair hearing. Ultimately, however, “decisions about the risks and benefits of Cox-2s and other drugs should almost always rest with doctors and patients, not Washington bureaucrats.”
|home spotlight commentary research events news about contact links archives|